This 2006 narrative review by Coleman synthesizes clinical data on the presentation, natural history, and prognostic factors of metastatic bone disease across cancer types. It asks: which patients are at highest risk for skeletal complications, and what clinical and biochemical features predict that risk? The review draws on large datasets including the zoledronic acid phase 3 program (~3,000 patients) to define actionable thresholds.
This 2006 narrative review by Coleman synthesizes clinical data on the presentation, natural history, and prognostic factors of metastatic bone disease across cancer types. It asks: which patients are at highest risk for skeletal complications, and what clinical and biochemical features predict that risk? The review draws on large datasets including the zoledronic acid phase 3 program (~3,000 patients) to define actionable thresholds.